Refine Search

Search Results -

Terms	Documents
L43 and L17	0

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L44

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Monday, March 14, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L44	L43 and L17	0	L44
L43	L41 and blood plasma	16	L43
L42	L41 and blood plasma protein	0	L42
L41	L38 and L25	16	L41
L40	L38 and albumin near3 dimer	0	L40
L39	L38 and L7	0	L39
L38	L36 and L9	180	L38
L37	L36 and L7	0	L37
L36	L34 and L4	2263	L36
L35	L34 and L31	1	L35
L34	L33 and L1	2591	L34
L33	L29 and intradermal or intra-dermal or interdermal or inter-dermal or cutaneous or subcutaneous near3 injection	54790	L33

L32	L29 and dermal insert$$$ or dremal inject$$$	0	L32
L31	L29 and crosslink$$$ or cross(w)link$$$ or zerolink$$$ or zero(w) link$$$	1	L31
L30	L29 and soft tissue augment$$$	0	L30
L29	L28 and L21 or L23	13	L29
L28	L27 and L18	13	L28
L27	L26 and L1	556	L27
L26	L25 and L5	8681	L26
L25	L21 or L23 and skin$$ or dermis$$ or drmatol$$	9714	L25
L24	L21 and L13	0	L24
L23	L21 and L4	13	L23
L22	L21 and L10	0	L22
L21	L18 and L1	13	L21
L20	L18 and L7	0	L20
L19	L18 and soft tsuue augment$$$	0	L19
L18	L17 and intradermal$$ or intra(w)dermal$$ or interdermal$$ or inter(w) dermal$$	177	L18
L17	L13 and L14	8	L17
L16	L10 and anesthetic compound	0	L16
L15	L10 and anesthetic(w)compound	0	L15
L14	L10 and vitamin	131	L14
L13	L12 and L11	23	L13
L12	L10 and growth factor	361	L12
L11	L10 and enzyme inhibitor	33	L11
L10	L9 and lysine asparate or lysine glutamate	697	L10
L9	L8 and amide bond	7050	L9
L8	L7 and inject$$$ or administrat$$$	366715	L8
L7	L5 and albumin near3 dimer	64	L7
L6	L5 and albumin(w)dimer	0	L6
L5	L4 and soft tissue(w)augment$$$ or add$$$ or increas$$$ or enlarg$$$	7580762	L5
L4	L3 and crosslink$$$ or cross(w)link$$$ or conjugat$$$ or join$$$ or bind$$$ or bound$$$	3740133	L4
L3	L1 and L2	2886	L3
L2	inject$$$ same material$$$	339516	L2
L1	Blood plasma	23679	L1

END OF SEARCH HISTORY

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, March 14, 2005

Hide?	Set Name	Query	Hit Count
	DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L23	L8 and (dimer|oligomer)	0
☐	L22	L8 and (crosslink|cross link|conjugat$5|bond$3|join$3)	0
☐	L21	L8 same (crosslink|cross link|conjugat$5|bond$3|join$3)	0
☐	L20	Ll8 same (crosslink|cross link|conjugat$5|bond$3|join$3)	0
☐	L19	l14 and intradermal	0
☐	L18	l12 and intradermal	0
	DB=PGPB,USPT; PLUR=YES; OP=ADJ		
☐	L17	l12 and intradermal	353
☐	L16	L14 with intradermal	2
☐	L15	L14 same intradermal	131
☐	L14	l8 with (crosslink|cross link|conjugat$5|bond$3|join$3) not (l9|l12)	6030
☐	L13	L12 same intradermal	2
☐	L12	l8 near5 (crosslink|cross link|conjugat$5|bond$3|join$3) not l9	2472
☐	L11	L9 and intradermal not l10	1160
☐	L10	L9 same intradermal	8
☐	L9	l8 near3 (crosslink|cross link|conjugat$5|bond$3|join$3)	8560
☐	L8	L7|l6	119690
☐	L7	(von willebrand|$globulin|fibronectin|albumin|fibrin$5)	114355
☐	L6	factor adj (II|III|IV|V|VI|VII|VIII|IX|X|XI|XII|XIII)	16107
☐	L5	L1 with fibrin$6 with albumin	202
☐	L4	L1 with fibrin$6	988
☐	L3	L1 with albumin	1161
☐	L2	L1 with albumin	1161
☐	L1	plasma protein	8618

END OF SEARCH HISTORY

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#

Generate Collection Print

L10: Entry 5 of 8 File: USPT Jun 22, 1993

DOCUMENT-IDENTIFIER: US 5221620 A
TITLE: Cloning and expression of transforming growth factor .beta.2

Drawing Description Text (124):
Synthetic peptides were conjugated to bovine gamma-globulin as described (Gentry et al., 1987, Mol. Cell. Biol. 7:3418-3427; Gentry and Lawton, 1986, Virology 152:421-431). New Zealand white rabbits were primed at three to six sites by combined subcutaneous and intradermal inoculations with the peptide conjugates (100 .mu.g equivalents of peptide) emulsified in Freunds complete adjuvant. Booster inoculations were administered at 2-3 week intervals. Rabbits were bled 7-14 days following the booster inoculations.

Previous Doc Next Doc Go to Doc#

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#

Generate Collection Print

L10: Entry 7 of 8 File: USPT May 20, 1986

DOCUMENT-IDENTIFIER: US 4590168 A

** See image for Certificate of Correction **

TITLE: Protein immunoassaying and purification

Detailed Description Text (17):

Antibodies useful in the erythropoietin assay are raised by immunizing New Zealand white rabbits with 50 .mu.g of the above-described polypeptide, preferably conjugated with bovine serum albumin (8.1 mg PP per 6.7 mg BSA, or approximately 20 molecules of PP per molecule of BSA) in Freund's complete adjuvant by multiple intradermal injections. Subcutaneous booster injections are administered over several weeks.

Previous Doc Next Doc Go to Doc#

```
* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:14:41 ON 14 MAR 2005

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
      AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
      BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
      CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:15:08 ON 14 MAR 2005

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s factor (w) (II or III or IV or V or VI or VII or VIII or IX or X or XI or XII or XIII)
        778   FILE ADISCTI
         95   FILE ADISINSIGHT
        307   FILE ADISNEWS
        454   FILE AGRICOLA
        138   FILE ANABSTR
          8   FILE ANTE
          2   FILE AQUALINE
         81   FILE AQUASCI
        609   FILE BIOBUSINESS
        624   FILE BIOCOMMERCE
        534   FILE BIOENG
      34652   FILE BIOSIS
  12 FILES SEARCHED...
       1903   FILE BIOTECHABS
       1903   FILE BIOTECHDS
       7630   FILE BIOTECHNO
       1319   FILE CABA
       6158   FILE CANCERLIT
      29597   FILE CAPLUS
  18 FILES SEARCHED...
        309   FILE CEABA-VTB
         39   FILE CEN
        495   FILE CIN
        953   FILE CONFSCI
          1   FILE CROPB
         11   FILE CROPU
       2270   FILE DDFB
       4034   FILE DDFU
      18376   FILE DGENE
  27 FILES SEARCHED...
        764   FILE DISSABS
       2270   FILE DRUGB
        576   FILE DRUGMONOG2
       4947   FILE DRUGU
        248   FILE EMBAL
      24601   FILE EMBASE
       6977   FILE ESBIOBASE
  34 FILES SEARCHED...
        396   FILE FEDRIP
         91   FILE FROSTI
         81   FILE FSTA
       6345   FILE GENBANK
         36   FILE HEALSAFE
       2506   FILE IFIPAT
        233   FILE IMSDRUGNEWS
        413   FILE IMSPRODUCT
         88   FILE IMSRESEARCH
       3050   FILE JICST-EPLUS
```

```
         7   FILE KOSMET
      3943   FILE LIFESCI
  48 FILES SEARCHED...
     39299   FILE MEDLINE
        50   FILE NIOSHTIC
       206   FILE NTIS
        19   FILE OCEAN
     13452   FILE PASCAL
  55 FILES SEARCHED...
       449   FILE PHAR
       224   FILE PHARMAML
         1   FILE PHIC
      1254   FILE PHIN
      2794   FILE PROMT
       134   FILE PROUSDDR
        10   FILE RDISCLOSURE
     35897   FILE SCISEARCH
     12930   FILE TOXCENTER
     14383   FILE USPATFULL
  68 FILES SEARCHED...
       933   FILE USPAT2
        21   FILE VETB
        67   FILE VETU
        18   FILE WATER
      2743   FILE WPIDS
  73 FILES SEARCHED...
        11   FILE WPIFV
      2743   FILE WPINDEX

  68 FILES HAVE ONE OR MORE ANSWERS,   75 FILES SEARCHED IN STNINDEX

L1    QUE FACTOR (W) (II OR III OR IV OR V OR VI OR VII OR VIII OR IX OR X OR XI
          OR XII OR XIII)

=> s (von willebrand or immunoglobin or globulin or fibronectin or albumin or fibrin#####)
       7844   FILE ADISCTI
        540   FILE ADISINSIGHT
       1540   FILE ADISNEWS
       6598   FILE AGRICOLA
       5231   FILE ANABSTR
        392   FILE ANTE
        138   FILE AQUALINE
       1598   FILE AQUASCI
       3823   FILE BIOBUSINESS
        998   FILE BIOCOMMERCE
       4732   FILE BIOENG
     262115   FILE BIOSIS
       6753   FILE BIOTECHABS
       6753   FILE BIOTECHDS
      39767   FILE BIOTECHNO
      29170   FILE CABA
      31723   FILE CANCERLIT
  17 FILES SEARCHED...
     238518   FILE CAPLUS
       1662   FILE CEABA-VTB
         64   FILE CEN
        750   FILE CIN
       4041   FILE CONFSCI
         76   FILE CROPB
        363   FILE CROPU
      16065   FILE DDFB
      29953   FILE DDFU
      45735   FILE DGENE
       5656   FILE DISSABS
      16065   FILE DRUGB
        824   FILE DRUGMONOG2
      40651   FILE DRUGU
        999   FILE EMBAL
     179104   FILE EMBASE
```

```
     36975   FILE ESBIOBASE
      1745   FILE FEDRIP
         3   FILE FOMAD
 36 FILES SEARCHED...
        18   FILE FOREGE
      2659   FILE FROSTI
      6161   FILE FSTA
     16109   FILE GENBANK
       405   FILE HEALSAFE
     11347   FILE IFIPAT
       273   FILE IMSDRUGNEWS
       703   FILE IMSPRODUCT
       261   FILE IMSRESEARCH
     61486   FILE JICST-EPLUS
       231   FILE KOSMET
     24249   FILE LIFESCI
        62   FILE MEDICONF
    231676   FILE MEDLINE
      2611   FILE NIOSHTIC
      2570   FILE NTIS
        10   FILE NUTRACEUT
       324   FILE OCEAN
     72491   FILE PASCAL
      2238   FILE PCTGEN
       553   FILE PHAR
       248   FILE PHARMAML
         4   FILE PHIC
      1820   FILE PHIN
      5830   FILE PROMT
      2552   FILE PROUSDDR
         1   FILE PS
 63 FILES SEARCHED...
       118   FILE RDISCLOSURE
    145258   FILE SCISEARCH
        18   FILE SYNTHLINE
     96319   FILE TOXCENTER
     95015   FILE USPATFULL
      5607   FILE USPAT2
       477   FILE VETB
      1995   FILE VETU
       158   FILE WATER
     15837   FILE WPIDS
        52   FILE WPIFV
     15837   FILE WPINDEX

 75 FILES HAVE ONE OR MORE ANSWERS,   75 FILES SEARCHED IN STNINDEX

L2   QUE (VON WILLEBRAND OR IMMUNOGLOBIN OR GLOBULIN OR FIBRONECTIN OR ALBUMIN
        OR FIBRIN#####)

=> s (l1 or l2) and (crosslink or cross link or conjugat##### or bond### or join###)
       426   FILE ADISCTI
       127   FILE ADISINSIGHT
       105   FILE ADISNEWS
       356   FILE AGRICOLA
      1100   FILE ANABSTR
        33   FILE ANTE
        15   FILE AQUALINE
       111   FILE AQUASCI
       417   FILE BIOBUSINESS
        42   FILE BIOCOMMERCE
       591   FILE BIOENG
     12885   FILE BIOSIS
 12 FILES SEARCHED...
      1093   FILE BIOTECHABS
      1093   FILE BIOTECHDS
      4017   FILE BIOTECHNO
      1497   FILE CABA
      1559   FILE CANCERLIT
```

```
     21368   FILE CAPLUS
  18 FILES SEARCHED...
       111   FILE CEABA-VTB
        32   FILE CEN
        84   FILE CIN
        43   FILE CONFSCI
         3   FILE CROPB
       119   FILE CROPU
      1083   FILE DDFB
      2952   FILE DDFU
      6680   FILE DGENE
  27 FILES SEARCHED...
       663   FILE DISSABS
      1083   FILE DRUGB
      4400   FILE DRUGU
        50   FILE EMBAL
     11008   FILE EMBASE
      2437   FILE ESBIOBASE
  34 FILES SEARCHED...
       181   FILE FEDRIP
       179   FILE FROSTI
       564   FILE FSTA
      1292   FILE GENBANK
        36   FILE HEALSAFE
      3326   FILE IFIPAT
        16   FILE IMSDRUGNEWS
        34   FILE IMSRESEARCH
      4359   FILE JICST-EPLUS
  46 FILES SEARCHED...
        11   FILE KOSMET
      2091   FILE LIFESCI
        10   FILE MEDICONF
     11414   FILE MEDLINE
       283   FILE NIOSHTIC
       179   FILE NTIS
        15   FILE OCEAN
  54 FILES SEARCHED...
      3467   FILE PASCAL
        60   FILE PHAR
        58   FILE PHARMAML
       559   FILE PHIN
      1421   FILE PROMT
  61 FILES SEARCHED...
        30   FILE PROUSDDR
        39   FILE RDISCLOSURE
      7897   FILE SCISEARCH
         2   FILE SYNTHLINE
      8762   FILE TOXCENTER
     74947   FILE USPATFULL
  68 FILES SEARCHED...
      4644   FILE USPAT2
        23   FILE VETB
       353   FILE VETU
        14   FILE WATER
      3287   FILE WPIDS
  73 FILES SEARCHED...
         5   FILE WPIFV
      3287   FILE WPINDEX

  67 FILES HAVE ONE OR MORE ANSWERS,  75 FILES SEARCHED IN STNINDEX

L3    QUE (L1 OR L2) AND (CROSSLINK OR CROSS LINK OR CONJUGAT##### OR BOND### OR
          JOIN###)

=> s (l1 or l2) (L) (crosslink or cross link or conjugat##### or bond### or join###)
       187   FILE ADISCTI
        72   FILE ADISINSIGHT
       105   FILE ADISNEWS
       322   FILE AGRICOLA
```

```
     1044   FILE ANABSTR
       28   FILE ANTE
       15   FILE AQUALINE
       82   FILE AQUASCI
      399   FILE BIOBUSINESS
       42   FILE BIOCOMMERCE
      548   FILE BIOENG
    10414   FILE BIOSIS
12 FILES SEARCHED...
     1069   FILE BIOTECHABS
     1069   FILE BIOTECHDS
     3751   FILE BIOTECHNO
     1428   FILE CABA
     1373   FILE CANCERLIT
    17848   FILE CAPLUS
18 FILES SEARCHED...
      104   FILE CEABA-VTB
       32   FILE CEN
       80   FILE CIN
       43   FILE CONFSCI
        3   FILE CROPB
      119   FILE CROPU
      828   FILE DDFB
     2549   FILE DDFU
     6265   FILE DGENE
27 FILES SEARCHED...
      657   FILE DISSABS
      828   FILE DRUGB
     3665   FILE DRUGU
       49   FILE EMBAL
     8734   FILE EMBASE
     2344   FILE ESBIOBASE
34 FILES SEARCHED...
      170   FILE FEDRIP
      165   FILE FROSTI
      437   FILE FSTA
     1227   FILE GENBANK
       36   FILE HEALSAFE
     2770   FILE IFIPAT
       15   FILE IMSDRUGNEWS
       31   FILE IMSRESEARCH
     3083   FILE JICST-EPLUS
       10   FILE KOSMET
     2013   FILE LIFESCI
48 FILES SEARCHED...
       10   FILE MEDICONF
     9217   FILE MEDLINE
      280   FILE NIOSHTIC
      142   FILE NTIS
       11   FILE OCEAN
     2986   FILE PASCAL
55 FILES SEARCHED...
       29   FILE PHAR
       58   FILE PHARMAML
      555   FILE PHIN
     1396   FILE PROMT
       28   FILE PROUSDDR
       39   FILE RDISCLOSURE
     6348   FILE SCISEARCH
        2   FILE SYNTHLINE
     8020   FILE TOXCENTER
67 FILES SEARCHED...
    69035   FILE USPATFULL
     4257   FILE USPAT2
       21   FILE VETB
      319   FILE VETU
       14   FILE WATER
72 FILES SEARCHED...
     2697   FILE WPIDS
```

```
  73 FILES SEARCHED...
         5   FILE WPIFV
      2697   FILE WPINDEX

  67 FILES HAVE ONE OR MORE ANSWERS,   75 FILES SEARCHED IN STNINDEX

L4    QUE (L1 OR L2) (L) (CROSSLINK OR CROSS LINK OR CONJUGAT##### OR BOND### OR
        JOIN###)

=> s (l1 or l2) (5a) (crosslink or cross link or conjugat##### or bond### or join###)
        74   FILE ADISCTI
        10   FILE ADISINSIGHT
         4   FILE ADISNEWS
       131   FILE AGRICOLA
       511   FILE ANABSTR
         8   FILE ANTE
        11   FILE AQUALINE
        43   FILE AQUASCI
       183   FILE BIOBUSINESS
        13   FILE BIOCOMMERCE
       237   FILE BIOENG
      4466   FILE BIOSIS
       264   FILE BIOTECHABS
       264   FILE BIOTECHDS
  14 FILES SEARCHED...
      1422   FILE BIOTECHNO
       715   FILE CABA
       597   FILE CANCERLIT
      9394   FILE CAPLUS
        32   FILE CEABA-VTB
         4   FILE CEN
        17   FILE CIN
        39   FILE CONFSCI
         3   FILE CROPB
  23 FILES SEARCHED...
        80   FILE CROPU
       362   FILE DDFB
       370   FILE DDFU
      1467   FILE DGENE
       180   FILE DISSABS
  28 FILES SEARCHED...
       362   FILE DRUGB
       620   FILE DRUGU
        13   FILE EMBAL
      3428   FILE EMBASE
       789   FILE ESBIOBASE
  34 FILES SEARCHED...
        22   FILE FEDRIP
        58   FILE FROSTI
       154   FILE FSTA
       153   FILE GENBANK
        29   FILE HEALSAFE
       290   FILE IFIPAT
         6   FILE IMSDRUGNEWS
         6   FILE IMSRESEARCH
       322   FILE JICST-EPLUS
         3   FILE KOSMET
  47 FILES SEARCHED...
       931   FILE LIFESCI
         1   FILE MEDICONF
      3597   FILE MEDLINE
       170   FILE NIOSHTIC
        41   FILE NTIS
         8   FILE OCEAN
      1073   FILE PASCAL
  55 FILES SEARCHED...
         6   FILE PHAR
         6   FILE PHARMAML
        31   FILE PHIN
```

```
        120   FILE PROMT
          4   FILE PROUSDDR
          3   FILE RDISCLOSURE
       2315   FILE SCISEARCH
       4295   FILE TOXCENTER
  67 FILES SEARCHED...
       4133   FILE USPATFULL
        156   FILE USPAT2
         20   FILE VETB
        146   FILE VETU
          6   FILE WATER
        494   FILE WPIDS
  73 FILES SEARCHED...
          1   FILE WPIFV
        494   FILE WPINDEX

  66 FILES HAVE ONE OR MORE ANSWERS,    75 FILES SEARCHED IN STNINDEX

L5    QUE (L1 OR L2) (5A) (CROSSLINK OR CROSS LINK OR CONJUGAT##### OR BOND### O
        R JOIN###)

=> s l5 (10a) intradermal
          1   FILE ADISCTI
          7   FILE BIOSIS
  13 FILES SEARCHED...
          2   FILE BIOTECHNO
          1   FILE CABA
         10   FILE CAPLUS
  19 FILES SEARCHED...
         12   FILE DDFB
          2   FILE DDFU
  27 FILES SEARCHED...
         12   FILE DRUGB
          3   FILE DRUGU
         12   FILE EMBASE
          1   FILE ESBIOBASE
  34 FILES SEARCHED...
          1   FILE IFIPAT
          3   FILE JICST-EPLUS
  48 FILES SEARCHED...
          6   FILE MEDLINE
          1   FILE PASCAL
  55 FILES SEARCHED...
          2   FILE SCISEARCH
         11   FILE TOXCENTER
  67 FILES SEARCHED...
          3   FILE USPATFULL
          2   FILE VETB
          2   FILE VETU
          1   FILE WPIDS
  73 FILES SEARCHED...
          1   FILE WPINDEX

  22 FILES HAVE ONE OR MORE ANSWERS,    75 FILES SEARCHED IN STNINDEX

L6    QUE L5 (10A) INTRADERMAL

=> d rank
F1           12   DDFB
F2           12   DRUGB
F3           12   EMBASE
F4           11   TOXCENTER
F5           10   CAPLUS
F6            7   BIOSIS
F7            6   MEDLINE
F8            3   DRUGU
F9            3   JICST-EPLUS
F10           3   USPATFULL
F11           2   BIOTECHNO
```

```
F12          2   DDFU
F13          2   SCISEARCH
F14          2   VETB
F15          2   VETU
F16          1   ADISCTI
F17          1   CABA
F18          1   ESBIOBASE
F19          1   IFIPAT
F20          1   PASCAL
F21          1   WPIDS
F22          1   WPINDEX


=> file hits
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      20.06      20.27

FILE 'DDFB' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGB' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 ACS

FILE 'CAPLUS' ENTERED AT 15:35:14 ON 14 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:35:14 ON 14 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:35:14 ON 14 MAR 2005

FILE 'DRUGU' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'JICST-EPLUS' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'USPATFULL' ENTERED AT 15:35:14 ON 14 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'SCISEARCH' ENTERED AT 15:35:14 ON 14 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'VETB' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'ADISCTI' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'CABA' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 CAB INTERNATIONAL (CABI)
```

```
FILE 'ESBIOBASE' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'PASCAL' ENTERED AT 15:35:14 ON 14 MAR 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'WPIDS' ENTERED AT 15:35:14 ON 14 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s l6
   4 FILES SEARCHED...
   9 FILES SEARCHED...
  12 FILES SEARCHED...
  18 FILES SEARCHED...
L7          93 L6

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8           45 DUP REM L7 (48 DUPLICATES REMOVED)
                ANSWERS '1-12' FROM FILE DDFB
                ANSWERS '13-24' FROM FILE EMBASE
                ANSWERS '25-28' FROM FILE TOXCENTER
                ANSWERS '29-31' FROM FILE CAPLUS
                ANSWERS '32-33' FROM FILE BIOSIS
                ANSWERS '34-36' FROM FILE DRUGU
                ANSWERS '37-38' FROM FILE USPATFULL
                ANSWERS '39-40' FROM FILE VETB
                ANSWERS '41-42' FROM FILE VETU
                ANSWER '43' FROM FILE ADISCTI
                ANSWER '44' FROM FILE CABA
                ANSWER '45' FROM FILE WPIDS

=> s l8 and py<2000
   3 FILES SEARCHED...
   6 FILES SEARCHED...
   7 FILES SEARCHED...
  12 FILES SEARCHED...
  16 FILES SEARCHED...
  19 FILES SEARCHED...
L9          42 L8 AND PY<2000

=> d bib abs 1-42

L9    ANSWER 1 OF 42  DDFB  COPYRIGHT 2005 THE THOMSON CORP on STN
AN    1982-38182  DDFB   P S
TI    THE EFFECT OF ACTIVE IMMUNISATION ON DIGOXIN HANDLING AND RESPONSE.
AU    GRIFFITHS N M; HEWICK D S; STEVENSON I H
LO    DUNDEE,U.K.
SO    BRIT.J.PHARMACOL. (76, NO.2, SUPPL., 201P, 1982)
LA    English
DT    Journal

L9    ANSWER 2 OF 42  DDFB  COPYRIGHT 2005 THE THOMSON CORP on STN
AN    1981-51796  DDFB   P
TI    THE INFLUENCE OF CYCLOPHOSPHAMIDE AND 6-MERCAPTOPURINE ON THE IGG1 AND
      IGG2 IMMUNE RESPONSE IN GUINEA-PIGS.
AU    DROESSLER K; KLIMA F; AMBROSIUS H
LO    LEIPZIG,DDR.
SO    IMMUNOLOGY (44, NO.1, 61-66, 1981)
LA    English
DT    Journal
```

L9 ANSWER 3 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1980-13856 DDFB E
TI EFFECTS OF ACTIVE IMMUNIZATION AGAINST OESTRADIOL-17BETA, TESTOSTERONE OR PROGESTERONE ON RECEPTIVITY IN THE FEMALE RABBIT AND EVALUATION OF SPECIFICITY.
AU ELSAESSER F
LO NEUSTADT,GER.
SO J.REPROD.FERT. (58, NO.1, 213-18, **1980**)
LA English
DT Journal

L9 ANSWER 4 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1979-25618 DDFB M A
TI PRODUCTION OF ANTIBODY AGAINST T-2 TOXIN.
AU CHU F S; GROSSMAN S; WEI R D; MIROCHA C J
LO MADISON,WIS.,USA.
SO APPL.ENVIRON.MICROBIOL. (37, NO.1, 104-08, **1979**)
LA English
DT Journal

L9 ANSWER 5 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1979-22009 DDFB P E S
TI INCIDENCE OF IMMUNE COMPLEX NEPHRITIS FOLLOWING ACTIVE IMMUNISATION WITH A TESTOSTERONE-3-BSA CONJUGATE OR BSA ALONE.
AU WITTING C; WICKINGS E J; NIESCHLAG E
LO MUNSTER,GER.
SO ACTA ENDOCRINOL. (90, NO.3, 562-67, **1979**)
LA English
DT Journal

L9 ANSWER 6 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1978-10623 DDFB E
TI A STUDY OF ANTIBODY PRODUCTION FOR THE RADIOIMMUNOASSAY OF GASTRIN.
AU FABRI P J; MCGUIGAN J E
LO GAINESVILLE,FLA.,USA.
SO AM.J.DIG.DIS. (22, NO.10, 902-08, **1977**)
DT Journal

L9 ANSWER 7 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1977-13365 DDFB E
TI HIGH TITER GLUCAGON ANTISERA.
AU TAGER H S; HOHENBOKEN M; MARKESE J
LO CHICAGO,ILL.,USA.
SO ENDOCRINOLOGY (100, NO.2, 36772, **1977**)
DT Journal

L9 ANSWER 8 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1976-30651 DDFB E
TI THE SPECIFICITY OF ANTISERA RAISED BY OESTRADIOL-17BETA-3-HEMISUCCINYL-BOVINE SERUM ALBUMIN.
AU EXLEY D; WOODHAMS B
LO LONDON,U.K.
SO STEROIDS (27, NO.6, 813-20, **1976**)
DT Journal

L9 ANSWER 9 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1976-21563 DDFB E A
TI OPTIMIZATION OF ANTIBODY PRODUCTION FOR RADIOIMMUNOASSAY OF GASTRIN.
AU FABRI P J; MCGUIGAN J E
LO GAINESVILLE,FLA.,USA.
SO GASTROENTEROLOGY (70, NO.5, PT.2, 883, **1976**)
DT Journal

L9 ANSWER 10 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1975-28681 DDFB S P
TI CORRELATION BETWEEN SPECIFIC IMMUNITY TO A METABOLITE OF HALOTHANE AND HEPATIC LESIONS AFTER MULTIPLE EXPOSURES.
AU MATHIEU A; DIPADUA D; KAHAN B D; GALDABINI J J; MILLS J

LO BOSTON,MASS.AND CHICAGO,ILL.,USA.
SO ANESTH.ANALG.CURR.RES. (54, NO.3, 332-39, **1975**)
DT Journal

L9 ANSWER 11 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1974-21269 DDFB E
TI LOSS OF SEXUAL ACTIVITY IN RABBITS ACTIVELY IMMUNIZED WITH TESTOSTERONE.
AU NIESCHLAG E; KLEY H K
LO DUSSELDORF,GER.
SO EXPERIENTIA (30, NO.4, 434-35, **1974**)
DT Journal

L9 ANSWER 12 OF 42 DDFB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1973-28283 DDFB T
TI IMMUNOTHERAPY OF MALIGNANT MELANOMA. A CLINICAL TRIAL.
AU MCCARTHY W H; COTTON G; CARLON A; MILTON G W; KOSSARD S
LO SYDNEY,AUSTR.
SO CANCER (32, NO.1, 97-103, **1973**)
DT Journal

L9 ANSWER 13 OF 42 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 97249824 EMBASE
DN 1997249824
TI Bronchial hyperresponsiveness, epithelial damage, and airway eosinophilia after single and repeated allergen exposure in a rat model of anhydride-induced asthma.
AU Cui Z.-H.; Sjostrand M.; Pullerits T.; Andius P.; Skoogh B.-E.; Lotvall J.
CS Dr. Z.-H. Cui, Lung Pharmacology Group, Department of Clinical Pharmacology, Sahlgrenska University Hospital, Guldhedsgatan 10A, 413 46 Goteborg, Sweden
SO Allergy: European Journal of Allergy and Clinical Immunology, (1997) 52/7 (739-746).
Refs: 29
ISSN: 0105-4538 CODEN: LLRGDY
CY Denmark
DT Journal; Article
FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis
026 Immunology, Serology and Transplantation
LA English
SL English
AB Bronchial hyperresponsiveness (BHR) and damage of the epithelium, as well as eosinophilia in the airway wall, induced by trimellitic anhydride (TMA) in sensitized brown Norway rats were studied. Rats were challenged once or seven times with aerosol of TMA **conjugated** to rat serum **albumin** (TMA-RSA) 3 weeks after **intradermal** TMA sensitization. Airway responsiveness (-log PC300 of acetylcholine i.v.) was measured 24 h after allergen challenge. Epithelial lesion and eosinophil infiltration in the airway walls were quantified under light microscopy, and TMA-specific IgE and IgG in serum were evaluated with ELISA. High levels of TMA-specific IgE and IgG were found in all rats in the sensitized groups compared to nonsensitized groups ($P<0.001$). Repeated allergen challenges of 0.03% TMA-RSA for 7 consecutive days enhanced the level of TMA-specific IgG, compared to single challenge ($P\leq0.05$). Single allergen challenge of 0.3% TMA-RSA had a nonsignificant tendency to produce BHR in sensitized rats compared to nonsensitized rats ($P=0.06$). However, repeated allergen challenges (0.003% and 0.03% TMA-RSA for 7 consecutive days) produced significant BHR in sensitized rats ($P<0.05$). Furthermore, repeated low-dose (0.003%) TMA-RSA challenge produced more BHR than a 10 times higher single dose (0.03%) ($P<0.05$). Slight damage of the airway epithelium was seen in sensitized and repeat-challenged groups. However, bronchial eosinophilia was found in the sensitized and single-challenged groups, but not in nonsensitized nonchallenged, and sensitized repeat- challenged groups ($P<0.005$). We conclude that the brown Norway rat can be sensitized with TMA, and that repeated low-dose allergen challenges produce slight epithelial damage and BHR which is independent of ongoing eosinophilia in the airway wall.

L9 ANSWER 14 OF 42 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN
AN 95321088 EMBASE
DN 1995321088
TI Antigenicity of balofloxacin (Q-35), novel fluoroquinolone antibacterial agent in guinea pigs and mice.
AU Marutani K.; Otabe Y.; Hara T.; Yahashi H.; Hasegawa T.; Tanaka K.
CS Toxicology Laboratory, Chugai Pharmaceutical Co. Ltd., 14016, Minamihara, Nakaminowa,Kamiina-gun, Nagano 399-46, Japan
SO Japanese Pharmacology and Therapeutics, (1995) 23/SUPPL. 6 (101-110). ISSN: 0386-3603 CODEN: YACHDS
CY Japan
DT Journal; Article
FS 030 Pharmacology
037 Drug Literature Index
LA Japanese
SL English; Japanese
AB Antigenicity of balofloxacin (Q-35), a newly developed fluoroquinolone antibacterial agent, was examined in guinea pigs and mice. The specific antibody production to Q-35 was evaluated by active systemic anaphylaxis (ASA), intradermal reaction and passive cutaneous anaphylaxis (PCA) reaction. Moreover, a direct Coombs' reaction was examined using human red blood cells. 1) Antigenicity in guinea pigs: When guinea pigs were administered unconjugated Q-35 orally or subcutaneously with Complete Freund's adjuvant, no anaphylactic response was observed by ASA, allogeneic 4-hour PCA and **intradermal** reactions using unconjugated Q-35 and **conjugated** Q-35 with bovine serum **albumin** (Q-35 BSA) as challenging antigens. In addition, when guinea pigs were sensitized with conjugated Q-35 with ovalbumin (Q-35-OVA) subcutaneously, definite ASA, PCA and dermal reactions were observed by eliciting of Q-35 BSA, but not by that of unconjugated Q-35. 2) Antigenicity in mice: When BALB/c and C3H/He mice were injected with aluminum hydroxide gel containing Q-35 or Q-35-OVA, no IgE antibody response was detected by heterologous 72-hour PCA reaction in rats using Q-35 alone and Q-35 BSA as eliciting antigens. 3) In vitro direct Coombs' reaction: No activity of Q-35 to produce direct Coorobs' reaction was observed in Miyagawa's method nor Molthan's method using human red blood cells. From these results, it could be concluded that Q-35 lacks the antigenicity to guinea pigs and mice under the present conditions.

L9 ANSWER 15 OF 42 EMBASE
on STN
AN 94016779 EMBASE
DN 1994016779
TI Antigenicity study of mosapride citrate.
AU Matsui Y.; Satomura K.; Nishiwaki T.; Matsuoka N.; Nakamura H.
CS Developmental Research Laboratories, Dainippon Pharmaceutical Co., Ltd., 33-94, Enoki-cho,Suita, Osaka 564, Japan
SO Japanese Pharmacology and Therapeutics, (1993) 21/10 (159-167). ISSN: 0386-3603 CODEN: YACHDS
CY Japan
DT Journal; Article
FS 026 Immunology, Serology and Transplantation
052 Toxicology
037 Drug Literature Index
LA English
SL English
AB Antigenicity of mosapride citrate, a new gastroprokinetic agent, was investigated in rabbits, guinea pigs and mice. Production of the antibody to mosapride citrate was detected in sera of rabbits and mice sensitized with mosapride-ovalbumin conjugate (mosapride-OVA) and Freund's complete adjuvant (FCA) or aluminium hydroxide gel (alum), but not with mosapride citrate and FCA or alum, when the antibody titers were determined by passive cutaneous anaphylactic (PCA) reaction using guinea pigs or rats, or by passive hemagglutination (PHA) reaction using sheep red blood cells. PCA reaction was not elicited by an intravenous challenge of mosapride citrate in guinea pigs and rats sensitized passively with antisera obtained from rabbits and mice, respectively, sensitized with mosapride-OVA and FCA or alum. In guinea pigs sensitized with mosapride-OVA and FCA, active anaphylactic reaction and delayed type skin

reaction (erythema) were elicited by intravenous and **intradermal** challenges, respectively, of mosapride-bovine serum **albumin conjugate**, but not by the challenge of mosapride citrate. From these results, it is suggested that mosapride citrate does not show antigenicity in the present test using rabbits, guinea pigs and mice.

L9 ANSWER 16 OF 42 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 92207625 EMBASE
DN 1992207625
TI Exogenously administered testosterone maintains spermatogenesis quantitatively in adult rats actively immunized against gonadotropin-releasing hormone.
AU Awoniyi C.A.; Zirkin B.R.; Chandrashekar V.; Schlaff W.D.
CS Dept. of Obstetrics and Gynecology, University of Colorado, Health Science Center, 4200 East Ninth Avenue,Denver, CO 80262, United States
SO Endocrinology, (1992) 130/6 (3283-3288).
ISSN: 0013-7227 CODEN: ENDOAO
CY United States
DT Journal; Article
FS 003 Endocrinology
026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
LA English
SL English
AB The administration of testosterone via Silastic capsules has been shown previously to maintain advanced spermatid number quantitatively in intact rats in which LH but not FSH was suppressed, but not in hypophysectomized rats, indicating that pituitary factors in addition to LH are required for the quantitative maintenance of spermatogenesis in the rat. The objective of the present study was to examine whether testosterone is capable of maintaining quantitatively normal spermatogenesis in rats in which both LH and FSH are suppressed. Intact adult male rats were actively immunized against GnRH by **intradermal** injection of GnRH **conjugated** to human serum **globulin**; control rats received **intradermal** injections of saline and adjuvant. Four weeks after the primary immunization, GnRH-immunized rats received the first booster injection and, at the same time, received testosterone-filled polydimethylsiloxane (PDS) implants of 4, 8, 12, or 24 cm or empty implants. Booster injections were repeated every 2 weeks for 8 weeks. At that time, rats were killed, and serum levels of LH, FSH, and testosterone, testicular advanced spermatid number, and seminiferous tubule fluid testosterone concentrations were determined. Four weeks after the initial administration of GnRH immunogen, i.e. before the first booster injection, serum levels of testosterone, LH, and FSH and the number of advanced spermatids per testis were not different from those in controls. Eight weeks after the first booster injection, serum LH and FSH and advanced spermatids were undetectable in all GnRH-immunized rats. The administration of testosterone-filled PDS implants of 4 and 8 cm to GnRH-immunized rats for 8 weeks resulted in the maintenance of 105 ± 6 and 161 ± 5 x 106 advanced spermatid/testis, respectively, significantly less than the control value (237 ± 19 x 106). In GnRH-immunized rats that received testosterone-filled PDS implants of 12 or 24 cm, the advanced spermatid numbers per testis (228 ± 4 and 229 ± 8 x 106, respectively) were not significantly different from those in controls. These results indicate that testosterone is capable of maintaining spermatogenesis quantitatively in the adult rats testis in the absence of both radioimmunoassayable LH and FSH.

L9 ANSWER 17 OF 42 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 90046566 EMBASE
DN 1990046566
TI Penicillin G-induced cutaneous anaphylaxis in the guinea pig.
AU Kubo K.; Nagatahira R.; Yoshida J.; Okuda T.; Yoshinaka I.; Kuriyama K.
CS Safety Evaluation Laboratories, Kaken Pharmaceutical Co. Ltd., 14 Minamikawara-cho, Shinomiya, Yamashina-ku, Kyoto 607, Japan
SO Journal of Toxicological Sciences, (1989) 14/4 (269-277).
ISSN: 0388-1350 CODEN: JTSCDR

CY Japan
DT Journal; Article
FS 013 Dermatology and Venereology
052 Toxicology
037 Drug Literature Index
LA English
SL English
AB Allergic cutaneous responses were induced by **intradermal** injection of penicillin G (PCG) and PCG-bovine serum **albumin** (BSA) **conjugates** onto the back of guinea pig actively immunized with PCG potassium (25 mg/animal) incorporated in Freund's complete adjuvant. The PCG-induced response was characterized macroscopically by erythema and edema with a maximum level at 24 hrs after elicitation and microscopically by the infiltration with basophils, macrophages and lymphocytes following with neutrophils. In addition, intensity of macrophage-infiltration shared a similar time course change with those of erythema and edema. These suggest that this response is associated to a delayed type hypersensitivity of Jones-Mote type. On the other hand, in the PCG-BSA-induced response the edema with erythema at the early phase was a noticeable observation and this response disappeared within 12 hrs, although the erythema continued by 24 hrs. Microscopically, the degranulation of mast cells and severe infiltration with neutrophils in the early phase and the infiltration of eosinophils in the late phase accompanying the infiltration with monocytes, basophils and lymphocytes were characteristic findings, which suggest that PCG-BSA response is a similar hypersensitivity to an atopic dermatitis. As mentioned above, we confirmed two types of allergic cutaneous responses in the guinea pig immunized with PCG.

L9 ANSWER 18 OF 42 EMBASE
on STN
AN 87232502 EMBASE
DN 1987232502
TI Induction of ethylenediamine hypersensitivity in the guinea pig and the development of ELISA and lymphocyte blastogenesis techniques for its characterization.
AU Babiuk C.; Hastings K.L.; Dean J.H.
CS Chemical Industry Institute of Toxicology, Department of Cell Biology, Research Triangle Park, NC 27709, United States
SO Fundamental and Applied Toxicology, (1987) 9/4 (623-634).
ISSN: 0272-0590 CODEN: FAATDF
CY United States
DT Journal
FS 013 Dermatology and Venereology
026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
035 Occupational Health and Industrial Medicine
046 Environmental Health and Pollution Control
052 Toxicology
LA English
AB Ethylenediamine (EDA) is reported to be a poorly characterized iatrogenic and occupational contact sensitizer. To better characterize EDA hypersensitivity, a guinea pig model was employed in which the animals were exposed epicutaneously to simulate conditions of human exposure, and selected immune parameters were measured. Induction of hypersensitivity was by the Buehler occluded patch method (6 hr application/day, once a week for 3 consecutive weeks) to 10, 20, 30, or 40% EDA, using either an ethanol or acetone/corn oil vehicle. Fourteen days after the last induction, guinea pigs were challenged by patch application of 2% EDA (nonirritating). The incidence of responders for erythema in the 10% EDA (ethanol) treatment group was 83 and 50% at 24 and 48 hr, respectively. In the 10% EDA (acetone/corn oil) group the corresponding values were 50 and 17%. For 20, 30, and 40% EDA, in either vehicle, the incidence of erythema was 83 to 100%. Severity grades (scale = 0-3) for cutaneous reactions to increasing concentrations of EDA in ethanol ranged from 0.8 to 2.5; those for EDA in acetone/corn oil ranged from 0.6 to 2.8. Using an enzyme-linked immunosorbent assay developed to detect the predominant serum antibodies to EDA, it was shown that guinea pigs treated by patch application did not produce the main allergic antibody IgG specific for EDA. However,

intradermal administration of an EDA-guinea pig serum **albumin conjugate** (EDA-GSA) to guinea pigs presensitized by patch application resulted in antibody production by 39 and 86% of the animals, at the initial and second dosing, respectively. An in vitro blastogenesis assay, using peripheral blood lymphocytes from EDA-sensitized guinea pigs, was developed to identify specific chemical allergens implicated in in vivo sensitization. Maximum tritiated thymidine ([3H]TdR) incorporation by lymphocytes stimulated in vitro with EDA-GSA was observed on Day 7. Optimal antigen concentration for maximum lymphocyte proliferation ranged from 5 to 50 μg/ml, the major variation being attributable to interanimal differences. These results indicate that epicutaneous application of EDA in the guinea pig induces a Type IV delayed hypersensitivity; immunological memory to the hapten is maintained in cultured lymphocytes, suggesting the potential usefulness of the lymphocyte transformation test for in vitro diagnosis of chemically induced hypersensitivity in humans.

L9 ANSWER 19 OF 42 EMBASE
on STN
AN 82252544 EMBASE
DN 1982252544
TI Induction of an allergic air-pouch inflammation in rats.
AU Tsurufuji S.; Yoshino S.; Ohuchi K.
CS Dep. Biochem., Fac. Pharm. Sci., Tohoku Univ., Aoba, Aramaki, Sendai, Japan
SO International Archives of Allergy and Applied Immunology, (1982) 69/3 (189-198).
CODEN: IAAAAM
CY Switzerland
DT Journal
FS 005 General Pathology and Pathological Anatomy
026 Immunology, Serology and Transplantation
013 Dermatology and Venereology
LA English
AB An allergic air pouch inflammation was induced on the dorsum of rats using azobenzenearsonate-**conjugated** acetyl bovine serum **albumin** as an antigen. Rats were immunized by **intradermal** injection with 5 mg of the antigen in 0.5 ml Freund's complete adjuvant saline (1:1) emulsion. 9 days after the immunization 8 ml of air was injected subcutaneously on the dorsum, and 24 h later 4 ml of 2% sodium carboxymethyl cellulose solution containing 2 mg of the antigen was injected into the preformed air pouch to provoke the allergic inflammation. In addition to the histological observations of the inflammatory tissues of the pouch wall, time course studies on the volume of the inflammatory pouch fluid, on the number and species of inflammatory cells in the pouch fluid and on wet weight of granulation tissues were carried out to characterize the nature of the inflammatory reaction, which was shown to be suitable as a model to perform quantitative measurements and biochemical analyses of the allergic inflammation.

L9 ANSWER 20 OF 42 EMBASE
on STN
AN 77214863 EMBASE
DN 1977214863
TI Antibody mediated basophil accumulations in cutaneous hypersensitivity reactions of guinea pigs.
AU Askenase P.W.; Haynes J.D.; Hayden B.J.
CS Dept. Med., Yale Univ. Sch. Med., New Haven, Conn. 06510, United States
SO Journal of Immunology, (1976) 117/5 I (1722-1730).
CODEN: JOIMA3
DT Journal
FS 026 Immunology, Serology and Transplantation
013 Dermatology and Venereology
004 Microbiology
025 Hematology
LA English
AB Cutaneous basophil hypersensitivity (CBH) was studied in guinea pigs by using simplified histologic techniques. Animals immunized with oxazolone or picryl conjugates of keyhole limpet hemocyanin (KLH) emulsified with

complete (CFA) or incomplete Freund's adjuvant (IFA) were found to have hapten specific cutaneous basophil reactions when skin tested at 1 week with oxazolone or picryl chloride contact painting or **intradermal** injection of oxazolone or picryl **conjugated** human serum **albumin**, respectively. Thus, hapten specific cutaneous basophil reactions were present in guinea pigs immunized with CFA for classical delayed hypersensitivity, and in animals immunized with IFA for Jones Mote reactions. Hapten specific 24 hr cutaneous basophil reactions were passively transferred with immune serum from donors sensitized with conjugates of oxazolone or picryl KLH in CFA or IFA, and with serum from oxazolone contact-sensitized animals as well. As little as 0.5 ml sera obtained from donors 1 week after immunization could systematically transfer cutaneous basophil reactions. It is likely that hapten-specific cutaneous basophil reactions are mediated by small quantities of serum antibodies. It is concluded that antibody-mediated cutaneous basophil reactions may be distinctive hypersensitivity responses that can be distinguished from classical anaphylactic, Arthus, and delayed hypersensitivities. It is suggested that CBH reactions are heterogeneous and that antibody products of B lymphocytes, and factors probably derived from T lymphocytes, play a role in basophil accumulations at cutaneous hypersensitivity reactions.

L9 ANSWER 21 OF 42 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 77186871 EMBASE
DN 1977186871
TI Production of anti luteinizing hormone releasing factor (LH-RF) serum: immunobiological application and development of radioimmunoassay.
AU Shiina M.
CS Dept. Obstet. Gynecol., Sch. Med., Keio Univ., Tokyo, Japan
SO JAP.J.FERTIL.STERIL., (1976) 21/4 (12-21).
CODEN: JJFSA5
DT Journal
FS 010 Obstetrics and Gynecology
003 Endocrinology
023 Nuclear Medicine
026 Immunology, Serology and Transplantation
LA English
AB A specific antiserum to luteinizing hormone releasing factor (LH-RF) was generated in female rabbits by repeated **intradermal** injections of LH-RF-bovine serum **albumin** (BSA) **conjugate** emulsified in Freund's complete adjuvant. In in vitro incubation, 20-30% binding of 125I-LH-RF and linear dose response relationship against cold LH-RF (the range from 2.5 to 2500 pg) were obtained using 1:1500-2000 dilutions of the antiserum. Compared with synthetic LH-RF, rat LH and FSH, substance P, oxytocin, lysine and arginine vasopressin, and synthetic TRF showed less than 0.03% displacement of LH-RF under these conditions. 200 μg of synthetic LH-RF were injected either i.v. or intramuscularly to healthy male adult. In the case of i.v. administration, the disappearance of exogenous LH-RF from the circulated blood was very rapid, and the half-life was 3.9 min within the first 15 min. I.v. injections of 0.8 ml of this antiserum to 4-day cycling female rats on proestrous day blocked ovulation on the following day. In these rats, LH surge on proestrous evening was blocked, however, LH was maintained at basal levels. At the time of about 1 yr after the first immunization, the 2 female rabbits which produced these antisera showed histologically marked atrophy of ovaries and uteri. Serum LH and 20α hydroxypregn 4 en 3 one concentrations in these rabbits were low but detectable by radioimmunoassays. These data indicate that the specific antiserum to LH-RF is applicable for biological experiments as well as for development of a radioimmunoassay of LH-RF.

L9 ANSWER 22 OF 42 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 77128638 EMBASE
DN 1977128638
TI Antibody mediated basophil accumulations in cutaneous hypersensitivity reactions of guinea pigs.
AU Askenase P.W.; Haynes J.D.; Hayden B.J.

CS Dept. Med., Yale Univ. Sch. Med., New Haven, Conn. 06510, United States
SO Journal of Immunology, (1976) 117/1 (216-224).
CODEN: JOIMA3
DT Journal
FS 026 Immunology, Serology and Transplantation
013 Dermatology and Venereology
LA English
AB Cutaneous basophil hypersensitivity (CBH) was studied in guinea pigs by using simplified histologic techniques. Animals immunized with oxazolone or picryl conjugates of keyhole limpet hemocyanin (KLH) emulsified with complete (CFA) or incomplete Freund's adjuvant (IFA) were found to have hapten specific cutaneous basophil reactions when skin tested at 1 week with oxazolone or picryl chloride contact painting or **intradermal** injection of oxazolone or picryl **conjugated** human serum **albumin**, respectively. Thus, hapten specific cutaneous basophil reactions were present in guinea pigs immunized with CFA for classical delayed hypersensitivity, and in animals immunized with IFA for Jones Mote reactions. Hapten specific 24 hr cutaneous basophil reactions were passively transferred with immune serum from donors sensitized with conjugates of oxazolone or picryl KLH in CFA or IFA, and with serum from oxazolone contact sensitized animals as well. As little as 0.5 ml sera obtained from donors 1 week after immunization could systemically transfer cutaneous basophil reactions. It is likely that hapten specific cutaneous basophil reactions are mediated by small quantities of serum antibodies. It is concluded that antibody mediated cutaneous basophil reactions may be distinctive hypersensitivity responses that can be distinguished from classical anaphylactic, Arthus, and delayed hypersensitivities. It is suggested that CBH reactions are heterogeneous and that antibody products of B lymphocytes, and factors probably derived from T lymphocytes, play a role in basophil accumulations at cutaneous hypersensitivity reactions.

L9 ANSWER 23 OF 42 EMBASE
on STN
AN 75097874 EMBASE
DN 1975097874
TI Radioimmunoassay for luteinizing hormone releasing factor (LH RF). Production of specific antibody and its biologic potency (Japanese).
AU Makino T.; Ohno T.; Shiina M.; et al.
CS Dept. Obstet. Gynecol., Tokyo Dent. Coll. Hosp., Tokyo, Japan
SO JAP.J.FERTIL.STERIL., (1974) 19/3 (18-21).
CODEN: JJFSA5
DT Journal
FS 037 Drug Literature Index
003 Endocrinology
026 Immunology, Serology and Transplantation
023 Nuclear Medicine
010 Obstetrics and Gynecology
LA Japanese
AB As one of the first steps toward developing a highly sensitive and specific radioimmunoassay for luteinizing hormone releasing factor (LH RF), the antibody to LH RF was generated by repeated **intradermal** injections of LH RF bovine serum **albumin** (BSA) **conjugate** solution emulsified in Freund's complete adjuvant to female rabbits. After the third booster injection, about 30% of binding to 125I LH RF was obtained at 1 : 1,000 dilution of the antiserum and a linear dose response relationship against cold LH RF was shown in the range from 0.25 ng to 10.0 ng. Rat LH and FSH, substance P, oxytocin, lysine and arginine vasopressin, and synthetic TRF showed less than 0.03% cross immunoreaction as compared with cold LH RF (100%). Two intravenous injections of 0.8 ml of this antiserum to 4 day cycling female rats at 1:00 p.m. and 3:00 p.m. on the proestrous day inhibited ovulation the next morning. The findings indicate that the method used is applicable for further development of radioimmunoassay for LH RF.

L9 ANSWER 24 OF 42 EMBASE
on STN
AN 74055791 EMBASE
DN 1974055791
TI Ovulation blockade in rats by rabbit anti luteinizing hormone releasing

factor serum.
AU Makino T.; Takahashi M.; Yoshinaga K.; Greep R.O.
CS Lab. Hum. Reproduct. Reprod. Biol., Harvard Med. Sch., Boston, Mass. 02115, United States
SO Contraception, (1973) 8/2 (133-145).
CODEN: CCPTAY
DT Journal
FS 037 Drug Literature Index
010 Obstetrics and Gynecology
003 Endocrinology
030 Pharmacology
026 Immunology, Serology and Transplantation
LA English
AB As one of the first steps toward developing a highly sensitive and specific radioimmunoassay for luteinizing hormone releasing factor (LRF), an antiserum to LRF was generated in female rabbits by repeated **intradermal** injections of LRF bovine serum **albumin** (BSA) **conjugate** emulsified in Freund's complete adjuvant. After the third booster injection, 30% binding of 125I LRF and a linear dose response relationship against cold LRF (0.25 ng to 10.0 ng) were obtained using a 1 : 1000 dilution of the antiserum. Compared with synthetic LRF, rat LH and FSH, substance P, oxytocin, lysine and arginine vasopressin, and synthetic TRF showed less than 0.3% displacement of LRF under these conditions. Intravenous injections of 1.0 ml of this antiserum to 4 day cycling female rats at 1:00 p.m. and 3:00 p.m. of the proestrous day blocked ovulation the next morning. The data indicate that this antiserum is appropriate for biological studies regarding gonadotropin release in addition to its use in developing a radioimmunoassay for LRF.

L9 ANSWER 25 OF 42 TOXCENTER COPYRIGHT 2005 ACS on STN
AN 2002:624056 TOXCENTER
DN RISKLINE-1997090010
TI Phenylisocyanat
AU Anonymous
SO Toxikologische Bewertung. Heidelberg, Berufsgenossenschaft der chemischen Industrie, (**1997**) 198 32 p.
FS RISKLINE
LA German
ED Entered STN: 20021200
Last Updated on STN: 20021200
AB Phenyl isocyanate is harmful on acute oral administration (LD50 rat oral 800 to 2750 mg/kg body weight). An oral LD50 value of 172 mg/kg body weight has been determined in the female rat in one study. LD50 values of 196 and 1600 mg/kg body weight have been reported after oral administration to the mouse. The acute dermal toxicity of phenyl isocyanate is low (LD50 rat dermal > 5000 mg/kg body weight; LD50 rabbit dermal > 2000 mg/kg body weight). In contrast, phenyl isocyanate is highly toxic on inhalation (4-hour LC50 rat 22 mg/m3 air). Delayed deaths occur particularly after inhalation exposure. The maximum possible saturation concentration of phenyl isocyanate at room temperature is about 600-fold higher than the LC50 value, and the inhalation hazard is thus severe. In the Alarie test, the concentration that reduces the respiratory frequency by 50% (RD50) depends on the duration of exposure, being 1.8 ppm (after 10 minutes), 1.2 ppm (30 minutes), 0.9 ppm (1 hour), 0.82 ppm (2 hours) and 0.73 ppm (3 hours), equivalent to 8.9, 5.9, 4.4, 4.0 and 3.6 mg/m3, respectively. An RD15 of 0.22 ppm, equivalent to 1.1 mg/m3, has been given for an exposure duration of 45 minutes. On repeated inhalation exposure of rats to phenyl isocyanate for 3 weeks, a concentration as low as 0.05 ppm, equivalent to 0.25 mg/m3, gave rise to mild inflammatory effects in the larynx, trachea and bronchial tree. After repeated inhalation exposure of rats for 4 weeks, irritation of the airways, cyanosis, hypothermia and effects on the red blood cell count occurred in a concentration-dependent manner from 2.79 mg/m3, and histopathological examination revealed local damage to the upper respiratory tract. A no effect level of 0.83 mg/m3 was given for this study. Phenyl isocyanate is severely irritating to the skin and corrosive to the eyes of rabbits. In the maximization test in guinea pigs, phenyl isocyanate induces skin sensitization in a concentration-dependent manner. Respiratory sensitization is only detectable in guinea pigs after

intradermal induction and inhalation challenge with a guinea pig **albumin**-phenyl isocyanate **conjugate.** A model has been described for rats, suggesting that respiratory sensitization to phenyl isocyanate may be likely for this species too. Phenyl isocyanate is not mutagenic in the Salmonella/microsome test, either with or without metabolic activation, and does not induce chromosome aberrations in vivo in the bone marrow of mice. It forms the corresponding phenylcarbamyl compounds with deoxyribonucleic acid in vitro. In preliminary studies in mice, phenyl isocyanate has shown no embryotoxic activity, although the protocol used does not permit a conclusive evaluation. In vitro, phenyl isocyanate inhibits acetyl cholinesterase activity in erythrocytes and whole blood, but this effect is described as comparatively weak. IgE antibodies that are specific for isocyanate-albumin conjugates can be detected in workers who have been exposed to isocyanates, including phenyl isocyanate.

L9 ANSWER 26 OF 42 TOXCENTER COPYRIGHT 2005 ACS on STN
AN 1995:195509 TOXCENTER
CP Copyright 2005 ACS
DN CA12317217796G
TI Antigenicity of balofloxacin (Q-35), novel fluoroquinolone antibacterial agent in guinea pigs and mice
AU Marutani, Kiyoshi; Otabe, Yohko; Hara, Toshiko; yahashi, Hiroyuki; Hasegawa, Takashi; Tanaka, Kouichi
CS Toxicology Laboratory, Chugai Pharmaceutical Co., Ltd., Minowa, 399-46, Japan.
SO Yakuri to Chiryo, (**1995**) Vol. 23, No. 6, Suppl., pp. s1617-s1626.
CODEN: YACHDS. ISSN: 0386-3603.
CY JAPAN
DT Journal
FS CAPLUS
OS CAPLUS 1995:781350
LA Japanese
ED Entered STN: 20011116
Last Updated on STN: 20020903
AB Antigenicity of balofloxacin (Q-35), a newly developed fluoroquinolone antibacterial agent, was examined in guinea pigs and mice. The specific antibody production to Q-35 was evaluated by active systemic anaphylaxis (ASA), intradermal reaction and passive cutaneous anaphylaxis (PCA) reaction. Moreover, a direct Coombs' reaction was examined using human red blood cells. 1) Antigenicity in guinea pigs: When guinea pigs were administered unconjugated Q-35 orally or s.c. with Complete Freund's adjuvant, no anaphylactic response was observed by ASA, allogeneic 4-h PCA and **intradermal** reactions using unconjugated Q-35 and **conjugated** Q-35 with bovine serum **albumin** (Q-35-BSA) as challenging antigens. In addition, when guinea pigs were sensitized with conjugated Q-35 with ovalbumin (Q-35-OVA) s.c., definite ASA, PCA and dermal reactions were observed by eliciting of Q-35-BSA, but not by that of unconjugated Q-35. 2) Antigenicity in mice: When BALB/c and C3H/He mice were injected with aluminum hydroxide gel containing Q-35 or Q-35-OVA, no IgE antibody response was detected by heterologous 72-h PCA reaction in rats using Q-35 alone and Q-35-BSA as eliciting antigens. 3) In vitro direct Coombs' reaction: No activity of Q-35 to produce direct Coombs' reaction was observed in Miyagawa's method nor Molthan's method using human red blood cells. From these results, it could be concluded that Q-35 lacks the antigenicity to guinea pigs and mice under the present conditions.

L9 ANSWER 27 OF 42 TOXCENTER COPYRIGHT 2005 ACS on STN
AN 1994:126786 TOXCENTER
CP Copyright 2005 ACS
DN CA12011124585K
TI Antigenicity study of mosapride citrate
AU Matsui, Yukiharu; Satomura, Kunihisa; Nishiwaki, Tsutomu; Matsuoka, Nobuo; Nakamura, Hideo
CS Dep. Res. Lab., Dainippon Pharm. Co., Ltd., Suita, 564, Japan.
SO Yakuri to Chiryo (1973-2000), (**1993**) Vol. 21, No. 10, pp. 3481-9.
CODEN: YACHDS. ISSN: 0386-3603.

CY JAPAN
DT Journal
FS CAPLUS
OS CAPLUS 1994:124585
LA Japanese
ED Entered STN: 20011116
Last Updated on STN: 20020917
AB Antigenicity of mosapride citrate (I), a new gastroprokinetic agent, was investigated in rabbits, guinea pigs and mice. Production of the antibody to mosapride citrate was detected in sera of rabbits and mice sensitized with mosapride-ovalbumin conjugate (mosapride-OVA) and Freund's complete adjuvant (FCA) or aluminum hydroxide gel (alum), but not with mosapride citrate and FCA or alum, when the antibody titers were determined by passive cutaneous anaphylactic (PCA) reaction using guinea pigs or rats, or by passive hemagglutination (PHA) reaction using sheep red blood cells. PCA reaction was not elicited by an i.v. challenge of mosapride citrate in guinea pigs and rats sensitized passively with antisera obtained from rabbits and mice, resp., sensitized with mosapride-OVA and FCA or alum. In guinea pigs sensitized with mosapride-OVA and FCA, active anaphylactic reaction and delayed type skin reaction (erythema) were elicited by i.v. and **intradermal** challenges, resp., of mosapride-bovine serum **albumin conjugate**, but not by the challenge of mosapride citrate. From these results, it is suggested that mosapride citrate does not show antigenicity in the present test using rabbits, guinea pigs and mice.

L9 ANSWER 28 OF 42 TOXCENTER COPYRIGHT 2005 ACS on STN
AN 1974:83046 TOXCENTER
CP Copyright 2005 ACS
DN CA08121134350V
TI Method for producing specific antiserum to luteinizing hormone releasing factor (LHRF)
AU Makino, T.; Takahashi, M.; Yoshinga, K.; Greep, R. O.
CS Lab. Hum. Reprod. Reprod. Biol., Harvard Med. Sch., Boston, MA, USA.
SO IRCS Library Compendium, (**1973**) Vol. 1, No. 4, pp. 15.3.6.
CODEN: IRLCAW. ISSN: 0305-2559.
CY UNITED STATES
DT Journal
FS CAPLUS
OS CAPLUS 1974:534350
LA English
ED Entered STN: 20011116
Last Updated on STN: 20021218
AB Specific antiserum to LHRF was produced in adult female rabbits by repeated **intradermal** immunization with synthetic LHRF-bovine serum **albumin conjugates** in Freund's complete adjuvant. The antiserum exhibited .apprx.35% specific binding to 125I-labeled-LHRF. Rat LH and FSH, substance P, oxytocin, lysine and argininevasopressin, and synthetic thyrotropin-releasing factor showed >0.03% immune cross-reaction as compared with cold LHRF (100%). The antiserum also inhibited ovulation, on injection into cycling female rats. Thus, the method used gave antiserum suitable for LHRF radioimmunoassay.

L9 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1980:73494 CAPLUS
DN 92:73494
TI Delayed luteal regression in ewes immunized against oxytocin
AU Flint, A. P. F.; Mitchell, M. D.; Sheldrick, E. Linda
CS ARC Inst. Anim. Physiol., Cambridge, CB2 4AT, UK
SO Journal of Physiology (Cambridge, United Kingdom) (**1979**), 296, 85P-86P
CODEN: JPHYA7; ISSN: 0022-3751
DT Journal
LA English
AB Ewes were immunized against oxytocin (I) by **intradermal** injection of 1 mg of I-bovine serum **albumin conjugate** (3.8 mol/mol **albumin**) at weekly intervals for 4 wk; the length of the estrous cycle was increased in ewes which showed an immune response to I. The increased cycle length was due to luteal phase prolongation.

Thus, immunization against I interferes with ovarian cyclicity.

L9 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1977:117135 CAPLUS
DN 86:117135
TI Development of a radioimmunoassay for oxytocin
AU Piron-Bossuyt, C.; Bossuyt, A.; Brauman, H.; Vanden Driessche, R.
CS Lab. Farmakol., Vrije Univ. Brussel, Brussels, Belg.
SO Annales d'Endocrinologie (**1976**), 37(5), 389-94
CODEN: ANENAG; ISSN: 0003-4266
DT Journal
LA English
AB High-affinity antibodies against oxytocin were produced in rabbits by multiple **intradermal** injections of an oxytocin-bovine serum **albumin conjugate** in complete Freund's adjuvant. The antibodies did not cross-react with lysine vasopressin. Reduction of the S-S link changed the immunoreactivity. The high affinity constant of the antibodies allows direct radioimmunoassay of oxytocin in dilute plasma (1:5) with a sensitivity of ≥4 μUnits/mL. Preliminary results for oxytocin determination in human unbilical cord plasma were 15-100 μUnits/mL.

L9 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1974:534350 CAPLUS
DN 81:134350
TI Method for producing specific antiserum to luteinizing hormone releasing factor (LHRF)
AU Makino, T.; Takahashi, M.; Yoshinga, K.; Greep, R. O.
CS Lab. Hum. Reprod. Reprod. Biol., Harvard Med. Sch., Boston, MA, USA
SO IRCS Library Compendium (**1973**), 1(4), 15.3.6
CODEN: IRLCAW; ISSN: 0305-2559
DT Journal
LA English
AB Specific antiserum to LHRF was produced in adult female rabbits by repeated **intradermal** immunization with synthetic LHRF-bovine serum **albumin conjugates** in Freund's complete adjuvant. The antiserum exhibited .apprx.35% specific binding to 125I-labeled-LHRF. Rat LH and FSH, substance P, oxytocin, lysine and argininevasopressin, and synthetic thyrotropin-releasing factor showed >0.03% immune cross-reaction as compared with cold LHRF (100%). The antiserum also inhibited ovulation, on injection into cycling female rats. Thus, the method used gave antiserum suitable for LHRF radioimmunoassay.

L9 ANSWER 32 OF 42 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1984:258024 BIOSIS
DN PREV198477091008; BA77:91008
TI RAPID TIME PRODUCTION IN THE RABBIT OF ANTI TRI IODO THYRONINE ANTIBODIES AT HIGH TITER TO BE USED IN THE RADIO IMMUNOASSAY PRACTICE.
AU GIOVANNINI E [Reprint author]; TALESA V; FEDELI L; PALUMBO R
CS CATTEDRA BIOL ZOOL GENERALE UNIV, VIA GROTTE POSATORA, 60100 ANCONA
SO Annali Sclavo, (1982) Vol. 24, No. 5, pp. 443-455.
CODEN: ASCLAZ. ISSN: 0003-472X.
DT Article
FS BA
LA ENGLISH
AB A method for rapid production of high titer antibodies to triiodothyronine [T3] in rabbits was developed. The procedure utilizes a T3-bovine serum **albumin conjugate** and multiple **intradermal** injections. The resulting sera have application in radioimmunoassays for T3.

L9 ANSWER 33 OF 42 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1992-42069 DRUGU P E
TI Role of Inflammatory Mediators on Airway Responses in Sensitized Guinea Pigs Exposed to Trimellitic Anhydride (TMA) Conjugate.
AU Hayes J P; Lotvall J O; Barnes P J; Newman Taylor A J; Chung K F
LO London, United Kingdom
SO Am.Rev.Respir.Dis. (145, No. 4, Pt. 2, A502, 1992) 1 Tab.
CODEN: ARDSBL ISSN: 0003-0805

AV Dept. of Thoracic and Occupational and Environmental Medicine, National Heart and Lung Institute, Royal Brompton Hospital, London SE3 6LY, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature
AN 1992-42069 DRUGU P E
AB The contributions of i.v. chlorpheniramine (C, chlorphenamine), i.v. WEB-2086 (apafant), i.p. BW-4AC (BW-A4C) and aerosolized nedocromilsodium (NS) in the acute response to **intradermal** (i.d.) trimellitic anhydride (TMA) alone and **conjugated** to guinea-pig **albumin** (TMA-GPSA) administered by intratracheal instillation were investigated in guinea-pigs. C, NS and WEB-2086 inhibited the acute bronchoconstrictor response in this model but C alone inhibited the associated airway microvascular leak. Histamine release plays an important role in TMA-induced airway responses in this model. (congress abstract).
ABEX Guinea pigs were sensitized by i.d. injection of free TMA (0.1 ml of 0.3% TMA in corn oil). 21-28 Days after sensitization anesthetized guinea pigs were challenged with TMA-GPSA (50 ul) by tracheal instillation. Extravasation of Evans Blue dye (20 mg/kg) into the airway tissue was used to quantify airway microvascular leakage (MVL ng dye/mg tissue). Sensitized guinea pigs were pretreated with i.v. chlorpheniramine (C) (2.5 mg/kg), WEB-2086 (10 ug/kg), i.p. BW-4AC (50 mg/kg), aerosolized nedocromil sodium (NS) (2%) or vehicle. Peak lung resistance (24.2 cmH2O/ml/sec) was inhibited by C (2.8), NS (5.5) and WEB (5.8), but not BW (13.3) compared to controls (0.9). MVL was only inhibited by C. MVL values in trachea, main bronchi, proximal intrapulmonary airways and distal intrapulmonary airways were 49, 55, 48 and 47 ng/mg with C, 89, 94, 75 and 74 ng/mg with WEB-2086, 102, 105, 89 and 77 ng/mg with BW-A4C, 80, 86, 86 and 85 ng/mg with N and 34, 33, 39 and 42 ng/mg in controls, respectively. (ECW)

L9 ANSWER 34 OF 42 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1985-48646 DRUGU P
TI The Serum Pharmacokinetics of Digoxin as an Immunogen and Hapten in the Rabbi
AU Griffiths N M; Hewick D S; Stevenson I H
LO Dundee, United Kingdom
SO Int.J.Immunopharmacol. (7, No. 5, 697-703, 1985) 4 Fig. 1 Tab. 10 Ref.
CODEN: IJIMDS ISSN: 0192-0561
AV Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, Scotland.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature
AN 1985-48646 DRUGU P
AB The elimination half-life of intradermal 3H-digoxin (3H-DI) rose with time after **intradermal** immunization using 3H-DI-human serum **albumin** (Sigma-Chemical) **conjugate** (DC) in Freunds complete adjuvant (Difco) from 2.0-24.8 days in rabbits. In immunized rabbits 3H-DI yielded 5-10 fold higher serum levels than in controls. A fall and subsequent increase in 3H-DI preceded elimination. DI-specific antibody titers did not change. Antibody titer was correlated with elimina tion half-life at the end of the study.
ABEX Male New Zealand/Half-Lop rabbits (2.0-2.6 kg) received 30 ug/kg 3H-DI 4 wk before and 6 and 44 wk after receiving 330 ug/kg DC in 0.1-0.2 ml adjuvant into several sites in the back. Antibody titers were determined by equilibrium dialysis. The pre-DC 3H-DI distribution half-life was 4.6 hr and elimination half-life 2.1 days. DC yielded a rapid fall in radioactivity lasting 0.5-1 day, a rise and fall on day 2 and in some rabbits a further rise and fall on days 2-4. The elimination half-life was 2.7 days. At 6 wk the mean peak serum level of 3H-DI was 5-fold higher than before DC and the mean elimination half-life was 4.1 days. At 44 wk the serum level was 10-fold above control. Serum levels fell for 2 days and rose. The elimination phase began on day 7 and the mean half-life was 24.8 days. Antibody titers were similar at wk 6 and 44.

Antibody titer correlated with elimination half-life at 44 but not 6 wk. Titer was unrelated to the 12-hr serum 3H-DI concentration. (W19/IMS)

L9 ANSWER 35 OF 42 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1984-04835 DRUGU P
TI Delta Sleep-Inducing Peptide (DSIP)-Like Material is Absorbed by the Gastrointestinal Tract of the Neonatal Rat.
AU Banks W A; Kastin A J; Coy D H
LO New Orleans, Louisiana, United States
SO Life Sci. (33, No. 16, 1587-97, 1983) 6 Fig. 19 Ref.
CODEN: LIFSAK ISSN: 0024-3205
AV Veterans Administration Medical Center, New Orleans, Louisiana 70146, U.S.A.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature
AN 1984-04835 DRUGU P
AB Delta sleep-inducing peptide (DP) like immunoreactivity entered into the circulation and the brain of neonatal rats fed with N-Tyr-DP (or 125I-N-Tyr-DP) or in rats nursed by mothers injected i.p. with N-Tyr -DP. Thus, a DP peptide given p.o. can be absorbed through the gastrointestinal tract into the systemic circulation.
ABEX Antibodies for RIA were raised in rabbits by **intradermal** injection of synthetic DSIP **conjugated** to alpha-human **globulin** with Freund's complete adjuvant. N-Tyr-DP was iodinated with chloramine-T and subsequently purified on a column of Sephadex G-25 and 2 ml fractions counted in a gamma counter. Separation of rat pup plasma on a column of G-15 Sephadex showed 5% immunoreactivity coeluted with des Trp-DP and 11% with DP. Recovery of peptide added to pup blood was 85.5 +/- 9.5%. The intra assay coefficient of variation was 11.3% and the intra assay variation was 13.7%. Immunoreactivity in blood from N-Tyr-DP treated rats (100 ug/rat) and in suckling pups whose mothers received N-Tyr-DP increased to a peak at 10 min. The blood and brain levels of radioactivity for 1-2 day old pups peaked at 20 and 40 min, respectively, and both peaked at 40 min for 10 day old pups fed 125I-N-Tyr-DP. Immunoreactivity in blood taken 10 min after feeding of 125I-N-Tyr-DP increased in the bound fraction and the regions co-eluting with des-Trp-DP and DP. Radioactivity in blood collected 20, 40 and 60 min after ingestion of 125I-N-Tyr-DP (10 power 5 CPM/rat) by 10 and 1-2 day pups eluted with the bound region and a region of iodinated peptide fragment radioactivity from the brains coeluted mainly with intact 125I-N-Tyr -DP.

L9 ANSWER 36 OF 42 USPATFULL on STN
AN 1999:141951 USPATFULL
TI Mono-- or diketone tetracyclic derivatives and therapeutical uses thereof
IN Boutherin-Falson, Odile, Palaiseau, France
Desquand-Billiald, Stephanie, Paris, France
Favrou, Anita, Cachan, France
Finet, Michel, Chatenay Malabry, France
Tembo, Olivier, Mery Sur Oise, France
Torregrosa, Jean-Luc, Cachan, France
Yannic-Arnoult, Sylvie, Epinay sur Orge, France
Joubert, Cecile, Sceaux, France
PA Laboratoire Innothera, Arcueil, France (non-U.S. corporation)
PI US 5981544 19991109 <--
WO 9721709 19970619 <--
AI US 1998-77435 19980921 (9)
WO 1996-FR1974 19961210
19980921 PCT 371 date
19980921 PCT 102(e) date
PRAI FR 1995-14684 19951212
DT Utility
FS Granted
EXNAM Primary Examiner: Mach, D. Margaret M.
LREP Kenyon & Kenyon
CLMN Number of Claims: 49

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1492
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Invention concerning the therapeutic use of tetracyclic derivatives and their pharmaceutically acceptable salts having the following general formula: ##STR1## in which, independently of the other: X is a carbon or nitrogen atom,

T is a carbon or nitrogen atom,

L is an oxygen atom or ketone functional protective group,

R.sub.1 is an atom of hydrogen, an atom of halogen, or a C.sub.1 to C.sub.5 alkyl radical,

R.sub.2 is a hydrogen atom, a halogen atom, a nitro radical, or a C.sub.1 to C.sub.5 alkyl radical,

n and m are equal to 0 or to 1, but not independently of the other, so that if n is equal to 1, then m is equal to 0, and if n is equal to 0, then m is equal to 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 37 OF 42 VETB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1982-62203 VETB E W N
TI RESPONSES OF RAM LAMBS TO ACTIVE IMMUNIZATION AGAINST TESTOSTERONE AND LUTEINIZING HORMONE-RELEASING HORMONE.
AU SCHANBACHER B D
LO CLAY CENTER,NEB.,USA.
SO AM.J.PHYSIOL. (242, NO.3, E201-E205, **1982**)
LA English
DT Journal

L9 ANSWER 38 OF 42 VETB COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1979-63802 VETB M C
TI CYTIDINE-5&-DIPHOSPHO-CHOLINE CONJUGATES. I. - SYNTHESIS AND FIXATION TO PHOSPHORYLCHOLINE-BINDING PROTEINS. II. - IMMUNOGENICITY IN RATS.
AU PERY P; LUFFAU G; CHARLEY J; PETIT A; ROUZE P; BERNARD S
LO THIVERVAL-GRIGNON,FR.
SO ANN.IMMUNOL. (130C, NO.4, 517-40, **1979**)
LA English
DT Journal

L9 ANSWER 39 OF 42 VETU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1991-61919 VETU E N
TI Effect of Cholecystokinin Immunization, Enhanced Food Intake and Growth of Swine on Lean Yield and Carcass Composition.
AU Pekas J C
LO Clay Center, Neb., USA
SO J.Nutr. (121, No. 4, 563-567, 1991) 3 Tab. 20 Ref.
CODEN: JONUAI
AV U.S. Department of Agriculture, Agricultural Research Service, Clay Center, NE 68933, U.S.A.
LA English
DT Journal
FA AB; LA; CT
AN 1991-61919 VETU E N
AB The effect of **intradermal** and s.c. immunization with cholecystokinin-octapeptide (CCK-8), **conjugated** to human serum **globulin**, on carcass leanness and composition of weanling pigs is reported. A previous study showed that CCK immunization enhanced feed intake by 8.2% and growth by 10.6% in these pigs. The heavier body weights of CCK immunized pigs resulted in heavier fresh and chilled carcasses and increases in lean, protein, fat- free dry matter, fat and bone yields.
ABEX CCK-8 was conjugated to human serum albumin and then emulsified in Freund complete adjuvant to give 1 mg/ml in 50% adjuvant for primary and in

Freund incomplete adjuvant for booster injections. 24 Weanling castrated male pigs (75-days-old, 25.6 kg) were given the primary dose s.c. and intradermally on day 1 and booster doses on days 29, 43 and 64. The pigs were killed on days 80. The CCK immunization had no effect on skin weight, carcass water content or on dressing percentage. In the immunized pigs, the chilled carcass weight was increased by 8.7% the total dry matter by 6.8%, the weight of the lean fraction by 2.7 kg (7.2%) and the fat fraction weight by 1.8 kg while the carcass length was 1.7 cm longer. The lean fractions of CCK immunized pigs contained 9.2% more protein and 5.1% more fat. The lean:fat and protein:fat ratios were not affected by immunization.

L9 ANSWER 40 OF 42 VETU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1986-62688 VETU N E
TI Effects on Growth and Body Composition of Androgen Deprivation by Castration or Autoimmunization to LH-Releasing Hormone in the Male Rat Under Conditions of Controlled Food Intake.
AU Fletcher J M; Lobley G E; Connell A
LO Aberdeen, U.K.
SO J.Endocrinol. (110, No. 1, 97-102, 1986) 1 Fig. 4 Tab. 21 Ref.
CODEN: JOENAK
AV Rowett Research Institute, Bucksburn, Aberdeen AB2 9SB, Scotland.
LA English
DT Journal
FA LA; CT
AN 1986-62688 VETU N E
AB The effects of autoimmunization to LHRH with LHRH (Sigma-Chemical) conjugated to ovine serum albumin were investigated on growth and body composition of male rats. Male rat carcasses contained more protein, less lipid and yielded more ash than females, but had the same amount of total energy. Intact and 19-day-old castrated rats did not differ in total carcass energy content or composition by 40-days-old. By 82-days-old, intact rat carcasses had more protein, and by day 131 protein content was higher and carcass lipid, energy and ash content were lower in intact rats. Sham castrated and 1-day-old castrated rats grew less well than 19-day-old castrated animals. Intact rats retained less carcass energy, less lipid and had less ash content than castrated and **intradermal** LHRH (Sigma-Chemical)-**albumin conjugate**-immunized rats.

L9 ANSWER 41 OF 42 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on STN
AN 1995:18376 ADISCTI
DN 800342885
TI Selective adverse reactions to diflunisal.
ADIS TITLE: Diflunisal: adverse reactions.
Skin disorders
In 2 patients.
AU Arias J; Fernandez Rivas M; Moral A; Garcia M A; Senent C J.
CS Hospital Virgen del Valle, Toledo, Spain.
SO Annals of Allergy, Asthma & Immunology (Feb 1, 1995), Vol. 74, pp. 160-162
DT Case
RE Rheumatic Disease
FS Summary
LA English
WC 364

L9 ANSWER 42 OF 42 CABA COPYRIGHT 2005 CABI on STN
AN 82:5660 CABA
DN 19820167196
TI Testicular function of actively immunized male rats with LH releasing hormone (LHRH): a possible role of prolactin on regulation of spermatogenesis
AU Shiota, K.; Takahashi, M.; Suzuki, Y.
CS Department of Veterinary Physiology, Faculty of Agriculture, Tokyo University, Bunkyo-ku, Tokyo 113, Japan.
SO Endocrinologia Japonica, (**1981**) Vol. 28, No. 4, pp. 521-534. 42 ref.
ISSN: 0013-7219

DT Journal
LA English
ED Entered STN: 19941101
Last Updated on STN: 19941101
AB Gonadotropin deficiency was induced in groups of 3-5 males by (1) hypophysectomy, (2) active immunisation against LHRH by **intradermal** injections of deaminated LHRH **conjugated** with bovine serum **albumin** at 2-wk intervals followed by a booster injection monthly, and (3) hypophysectomy plus immunisation plus a pituitary isograft; the effect of testosterone propionate on the recovery of spermatogenesis in the gonadotropin-deficient males was studied. Immunisation against LHRH produced the highest anti-LHRH titre 12 wk after treatment. Testis weight and testosterone production decreased markedly by 10 wk after treatment, and there was an associated drop in serum LH and FSH levels. The degree of testis atrophy was similar 3 months after treatment in long-term immunised and hypophysectomised males . Subcutaneous injection of 1 mg testosterone propionate per day for 30 days restored spermatogenesis in long-term immunised males . Simultaneous injection of anti-LH and anti-FSH sera in addition to testosterone did not affect the restoration of spermatogenesis in the long-term immunised males , but the treatment prevented the restoration of spermatogenesis in hypophysectomised males . However, when rats which had been immunised and hypophysectomised were given pituitary isografts, treatment with testosterone restored spermatogenesis. The serum prolactin level in immunised males was approx. 20% of that in untreated controls; treatment with testosterone increased the prolactin level of the former 2.5-fold. These results indicate that prolactin is involved in spermatogenesis.

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.90	199.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.19	-2.19

FILE 'STNGUIDE' ENTERED AT 15:46:47 ON 14 MAR 2005

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 11, 2005 (20050311/UP).

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.54	199.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.19

STN INTERNATIONAL LOGOFF AT 15:52:28 ON 14 MAR 2005